Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma
Completed · Phase 2
Conditions studied: Melanoma (Skin)
In brief
RATIONALE: Biological therapies, such as hu14.18-interleukin-2 fusion protein, may stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase II trial is studying how well hu14.18-interleukin-2 fusion protein works in treating patients with advanced melanoma.
Key facts
- Study ID
- NCT00109863
- Run by
- University of Wisconsin, Madison
- People needed
- 14
- Starts
- 2005-05-01
- Expected to finish
- 2014-02-01
- Last updated by the study team
- 2019-11-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Wisconsin Paul P. Carbone Comprehensive Cancer Center — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.